A ruthenium(II) hydride carbonyl complex with 4-phenylpyrimidine as co-ligand

The reaction of [RuHCl(CO)(PPh3)3] with 4-phenylpyrimidine gave a new ruthenium(II) complex, namely [RuHCl(CO)(PPh3)2(pyrim-4-Ph)]. The complex has been studied by IR and UV–vis spectroscopy and by X-ray crystallography. The molecular orbitals of the complex have been calculated by density functional theory. The spin-allowed singlet–singlet electronic transitions of the complex have been calculated by time-dependent DFT, and the UV–vis spectrum of the compound has been discussed on this basis. The emission properties of the complex were also studied

Molecular, spectroscopic, and magnetic properties of cobalt(II) complexes with heteroaromatic N(O)-donor ligands

New [Co(SCN)2(L)4/2] complexes, where L = b-pic (1), pyCH2OH (2), py(CH2)3OH (3), 1,2,4- triazolo[1,5-a]pyrimidine (4), [CoCl2(urotrop)2] (5), and [Co(DMIM)3]Cl2 H2O (6) where urotrop = hexamethylenetetramine and DMIM = 2,20-bis(4,5-dimethylimidazolyl) were synthesized in simple reactions of CoCl2 6H2O with ammonia thiocyanate and pyridine type ligands or urotropine and diimidazolyl ligands with cobalt(II) chloride in methanol solutions. The orthorhombic crystallization for (1), (2), and (4), the monoclinic one for (3) and (5) as well as the hexagonal one for (6) were found. The plots of the overlap population density-of-states indicated nonbonding character of the interactions between pyridine derivatives ligands and cobalt(II) ions in the complexes (1)–(4). The electronic spectra showed almost perfect octahedral complex in the case of (6). The magnetic susceptibility measurements revealed paramagnetic behavior with low values of the Curie–Weiss temperature, positive for complex (5) and negative for the other ones, although the transition to collective magnetic state at low temperatures for (4) and (5) was evidenced by an observation of antiferromagnetic coupling with Ne´el temperature of 4.5 K and the ferromagnetic one with Curie temperature of 10 K, respectively

Synthesis and anticancer activity of long-chain isonicotinic ester ligand-containing arene ruthenium complexes and nanoparticles

Arene ruthenium complexes containing long-chain N-ligands L1 = NC5H4-4-COO-C6H4-4-O-(CH2)9-CH3 or L2 = NC5H4-4-COO-(CH2)10-O-C6H4-4-COO-C6H4-4-C6H4-4-CN derived from isonicotinic acid, of the type [(arene)Ru(L)Cl2] (arene = C6H6, L = L1: 1; arene = p-MeC6H4Pr i , L = L1: 2; arene = C6Me6, L = L1: 3; arene = C6H6, L = L2: 4; arene = p-MeC6H4Pr i , L = L2: 5; arene = C6Me6, L = L2: 6) have been synthesized from the corresponding [(arene)RuCl2]2 precursor with the long-chain N-ligand L in dichloromethane. Ruthenium nanoparticles stabilized by L1 have been prepared by the solvent-free reduction of 1 with hydrogen or by reducing [(arene)Ru(H2O)3]SO4 in ethanol in the presence of L1 with hydrogen. These complexes and nanoparticles show a high anticancer activity towards human ovarian cell lines, the highest cytotoxicity being obtained for complex 2 (IC50 = 2 μM for A2780 and 7 μM for A2780cisR